These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 21895872)
1. MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Lakomy R; Sana J; Hankeova S; Fadrus P; Kren L; Lzicarova E; Svoboda M; Dolezelova H; Smrcka M; Vyzula R; Michalek J; Hajduch M; Slaby O Cancer Sci; 2011 Dec; 102(12):2186-90. PubMed ID: 21895872 [TBL] [Abstract][Full Text] [Related]
2. Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients. Tang K; Jin Q; Yan W; Zhang W; You G; Liu Y; Jiang T Med Oncol; 2012 Jun; 29(2):1292-6. PubMed ID: 21394635 [TBL] [Abstract][Full Text] [Related]
3. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients. Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189 [TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme. Limam S; Missaoui N; Abdessayed N; Mestiri S; Selmi B; Mokni M; Yacoubi MT Ann Biol Clin (Paris); 2019 Jun; 77(3):307-317. PubMed ID: 31131831 [TBL] [Abstract][Full Text] [Related]
5. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma. Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992 [TBL] [Abstract][Full Text] [Related]
6. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients. Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344 [TBL] [Abstract][Full Text] [Related]
7. Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival. Schaff LR; Yan D; Thyparambil S; Tian Y; Cecchi F; Rosenblum M; Reiner AS; Panageas KS; Hembrough T; Lin AL J Neurooncol; 2020 Jan; 146(1):163-170. PubMed ID: 31823165 [TBL] [Abstract][Full Text] [Related]
8. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Lalezari S; Chou AP; Tran A; Solis OE; Khanlou N; Chen W; Li S; Carrillo JA; Chowdhury R; Selfridge J; Sanchez DE; Wilson RW; Zurayk M; Lalezari J; Lou JJ; Ormiston L; Ancheta K; Hanna R; Miller P; Piccioni D; Ellingson BM; Buchanan C; Mischel PS; Nghiemphu PL; Green R; Wang HJ; Pope WB; Liau LM; Elashoff RM; Cloughesy TF; Yong WH; Lai A Neuro Oncol; 2013 Mar; 15(3):370-81. PubMed ID: 23328811 [TBL] [Abstract][Full Text] [Related]
9. The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival. Shu C; Wang Q; Yan X; Wang J Cancer Med; 2018 Aug; 7(8):3704-3712. PubMed ID: 29984907 [TBL] [Abstract][Full Text] [Related]
10. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis. Han Y; Yan LF; Wang XB; Sun YZ; Zhang X; Liu ZC; Nan HY; Hu YC; Yang Y; Zhang J; Yu Y; Sun Q; Tian Q; Hu B; Xiao G; Wang W; Cui GB BMC Cancer; 2018 Feb; 18(1):215. PubMed ID: 29467012 [TBL] [Abstract][Full Text] [Related]
11. Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics. Jiang S; Rui Q; Wang Y; Heo HY; Zou T; Yu H; Zhang Y; Wang X; Du Y; Wen X; Chen F; Wang J; Eberhart CG; Zhou J; Wen Z Eur Radiol; 2018 May; 28(5):2115-2123. PubMed ID: 29234914 [TBL] [Abstract][Full Text] [Related]
12. Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status. Romano A; Calabria LF; Tavanti F; Minniti G; Rossi-Espagnet MC; Coppola V; Pugliese S; Guida D; Francione G; Colonnese C; Fantozzi LM; Bozzao A Eur Radiol; 2013 Feb; 23(2):513-20. PubMed ID: 22875158 [TBL] [Abstract][Full Text] [Related]
13. Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma. Uno M; Oba-Shinjo SM; Camargo AA; Moura RP; Aguiar PH; Cabrera HN; Begnami M; Rosemberg S; Teixeira MJ; Marie SK Clinics (Sao Paulo); 2011; 66(10):1747-55. PubMed ID: 22012047 [TBL] [Abstract][Full Text] [Related]
14. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Rivera AL; Pelloski CE; Gilbert MR; Colman H; De La Cruz C; Sulman EP; Bekele BN; Aldape KD Neuro Oncol; 2010 Feb; 12(2):116-21. PubMed ID: 20150378 [TBL] [Abstract][Full Text] [Related]
15. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study. Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280 [TBL] [Abstract][Full Text] [Related]
16. Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Preusser M; Charles Janzer R; Felsberg J; Reifenberger G; Hamou MF; Diserens AC; Stupp R; Gorlia T; Marosi C; Heinzl H; Hainfellner JA; Hegi M Brain Pathol; 2008 Oct; 18(4):520-32. PubMed ID: 18400046 [TBL] [Abstract][Full Text] [Related]
17. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882 [TBL] [Abstract][Full Text] [Related]
18. The utilization of MGMT promoter methylation testing in United States hospitals for glioblastoma and its impact on prognosis. Lee A; Youssef I; Osborn VW; Safdieh J; Becker DJ; Schreiber D J Clin Neurosci; 2018 May; 51():85-90. PubMed ID: 29483008 [TBL] [Abstract][Full Text] [Related]
19. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. Melguizo C; Prados J; González B; Ortiz R; Concha A; Alvarez PJ; Madeddu R; Perazzoli G; Oliver JA; López R; Rodríguez-Serrano F; Aránega A J Transl Med; 2012 Dec; 10():250. PubMed ID: 23245659 [TBL] [Abstract][Full Text] [Related]
20. O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Brandes AA; Franceschi E; Tosoni A; Bartolini S; Bacci A; Agati R; Ghimenton C; Turazzi S; Talacchi A; Skrap M; Marucci G; Volpin L; Morandi L; Pizzolitto S; Gardiman M; Andreoli A; Calbucci F; Ermani M Neuro Oncol; 2010 Mar; 12(3):283-8. PubMed ID: 20167816 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]